Abstract | INTRODUCTION:
Immune checkpoint inhibitors (ICIs) have emerged as a promising class of cancer immunotherapies. Neurotoxicities are uncommon, but often severe, and potentially fatal complications of ICIs, and clinical experience is limited. The aim of this study is to further define the clinical spectrum and outcome of ICI-mediated neurotoxicities. METHODS: Patients with ICI-associated neurotoxicities were identified from retrospective review of the quality control database at a single institution. Data regarding demographics, medical history, clinical presentation, diagnosis, management and outcome were recorded. RESULTS: CONCLUSIONS: ICI-mediated neurotoxicities present early, are rapidly progressive and include a diverse phenotype affecting the CNS, PNS and neuroendocrine system. A high level of vigilance is warranted, as early diagnosis and targeted treatment can substantially prevent morbidity and mortality. Prospective clinical trials are warranted to assess optimized management of ICI-induced neurotoxicities.
|
Authors | Sophie L Duong, Frank J Barbiero, Richard J Nowak, Joachim M Baehring |
Journal | Journal of neuro-oncology
(J Neurooncol)
Vol. 152
Issue 2
Pg. 265-277
(Apr 2021)
ISSN: 1573-7373 [Electronic] United States |
PMID | 33454891
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Immune Checkpoint Inhibitors
- Ipilimumab
- Nivolumab
- atezolizumab
- pembrolizumab
|
Topics |
- Antibodies, Monoclonal, Humanized
(adverse effects)
- Humans
- Immune Checkpoint Inhibitors
(adverse effects)
- Ipilimumab
(adverse effects)
- Neoplasms
(drug therapy)
- Neurotoxicity Syndromes
(epidemiology, etiology)
- Nivolumab
(adverse effects)
- Retrospective Studies
|